# Niki BioSolutions Subsidiary Selected for Global Alzheimer Research Study

- URL: https://stocks.freetheai.org/news/niki-biosolutions-subsidiary-selected-for-global-alzheimer-research-study-674f1e
- Published: 2026-10-14T12:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:NIKI](https://stocks.freetheai.org/symbols/NASDAQ-NIKI)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Niki BioSolutions, Inc. (NIKI) announced that its subsidiary, DiamiR Biosciences Corp., will provide plasma-based APOE genotyping for participants in the Global Alzheimer’s Platform Foundation Bio-Hermes-002 research study. DiamiR will process banked plasma samples using its New York State-approved testing assay to add genetic risk data to the observational trial cohort.

The APOE epsilon 4 allele represents the strongest established genetic risk factor for late-onset Alzheimer's disease. Genotyping directly from existing blood samples allows researchers to evaluate genetic risk factors and refine clinical trial designs without requiring study participants to undergo additional blood draws. The resulting genetic information will be merged into the broader study database to assist biopharmaceutical and diagnostic firms studying neurodegenerative conditions.

Investors and industry observers will be monitoring how the research collaboration enhances DiamiR's visibility among commercial partners and diagnostic developers. Shares of Niki BioSolutions, Inc. (NIKI) traded down 13.08% to $2.625 following the news.

## Key points

- DiamiR Biosciences Corp., a subsidiary of Niki BioSolutions, Inc. (NIKI), will conduct APOE genotyping for the Bio-Hermes-002 study cohort.
- The testing uses banked plasma samples, adding genetic risk profile data without extra blood draws from participants.
- Resulting genetic data will be combined with the main study dataset for broader use by Alzheimer researchers.
- Shares of Niki BioSolutions, Inc. fell 13.08% to $2.625 on the day of the announcement.

## Questions and answers

### What is Niki BioSolutions doing with the Global Alzheimer's Platform Foundation?

Niki BioSolutions unit DiamiR will conduct plasma-based APOE genotyping on participant samples from the Bio-Hermes-002 Alzheimer study cohort.

### Why is plasma-based APOE genotyping useful in Alzheimer research?

It allows researchers to obtain critical genetic risk factor data from existing banked blood samples without requiring patients to undergo new blood draws.

### How did Niki BioSolutions stock react to the announcement?

Shares of Niki BioSolutions, Inc. (NIKI) dropped 13.08% to $2.625.